Merck & Co., Inc.
RAHWAY, NJ · CIK 310158 · 13F filing filed 2026-08-07
No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.
- Legal entityMERCK & CO., INC. (US)
Other 13F filers in this group: MERCK SHARP & DOHME LLC files a notice
This report includes the holdings of 1 other manager that shares the investment decisions:
- MERCK SHARP & DOHME LLC – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| PERSONALIS INC PSNL | $188.2m35.75% | Unchanged |
| MODERNA INC MRNA | $161.6m30.71% | Unchanged |
| KYMERA THERAPEUTICS INC KYMR | $88.5m16.82% | Unchanged |
| AKTIS ONCOLOGY INC AKTS | $30.7m5.83% | Unchanged |
| EIKON THERAPEUTICS INC EIKN | $21.7m4.13% | Unchanged |
| ENTRADA THERAPEUTICS INC TRDA | $12.8m2.43% | New |
| SUTRO BIOPHARMA INC STRO | $9.0m1.72% | New |
| ALECTOR INC ALEC | $7.1m1.35% | Unchanged |
| EVAXION AS EVAX | $3.8m0.71% | New |
| VIRIDIAN THERAPEUTICS INC VRDN | $1.7m0.33% | Unchanged |
| XILIO THERAPEUTICS INC XLO | $1.0m0.19% | Unchanged |
| TUHURA BIOSCIENCES INC HURA | $45.5k0.01% | Unchanged |
| NEUPHORIA THERAPEUTICS INC NEUP | $43.8k0.01% | Unchanged |
Sold out since Q1 2026
| Security | Value then |
|---|---|
| SUTRO BIOPHARMA INC | $6.8m272.4k shares |
| EVAXION BIOTECH A/S EVAX | $4.5m1.2m shares |
| CARISMA THERAPEUTICS INC CARM | $47.9k1.5m shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| EVAXION BIOTECH A/S EVAX · 13G · filed 2025-02-03 | 20.0% |
| PERSONALIS INC PSNL · 13G · filed 2024-12-23 | 16.5%≈ $188.2m |